This was an ancillary study to CTN-0030, a two-phase randomized controlled clinical trial of buprenorphine/naloxone treatment plus individual drug counseling for opioid analgesic dependence. All participants (648) randomized to Phase 1 of the CTN-0030 study were eligible for the ancillary study. Participants were assessed via telephone at 1.5, 2.5, and 3.5 years post-Phase 1 randomization into the CTN-0030 study. The study evaluated opioid use, quality of life, and pain.
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.